✓ Translated by DotMD AI Clinical Council Source: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #38955363 ↗

Randomized Controlled Trial: Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6

Original Paper Title: “Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.
  • Study Design & Sample: Randomized Controlled Trial published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2025), this randomized controlled trial evaluating human clinical outcomes investigated: This post hoc analysis explored the effects of semaglutide on estimated glomerular filtration (eGFR) slope by baseline glycemic control, blood pressure (BP), body mass index (BMI) and albuminuria status in people with type 2 diabetes and high cardiovascular risk. Key clinical takeaway: A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025-02-04; Randomized Controlled Trial; Rigor 88/100): A clinically meaningful reduction in risk of chronic kidney disease progression was observed with semaglutide versus placebo regardless of HbA1c, BP, BMI, and UACR levels.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: semaglutide → Rx: oral-semaglutide → Rx: pressure-pain-and-mucus-acetaminophen-guaifenesin-phenylephrine-hcl → Rx: sinus-pressure-plus-pain-pe-acetaminophen-and-phenylephrine → Condition: body-weight → Condition: diabetes →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 38955363: Randomized Controlled Trial: Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6

3 of 3 Free Questions Remaining